Mcl-1 downregulation sensitizes glioma to bortezomib-induced apoptosis

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2277-2284

  Zhang, Yang ^a   Zhu, Xiaobo ^a   Hou, Kun ^a   Zhao, Jinchuan ^a   Han, Zhiguo ^b   Zhang, Xiaona ^a  

^a JILIN UNIVERSITY   (China)

^b Traditional Chinese Medical Hospital of Gongzhuling   (China)

Author keywords

Apoptosis; Bortezomib; Glioma; Mcl 1; Proteasome inhibitors

Indexed keywords

BORTEZOMIB; CASPASE 3; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MCL 1; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; GENE SILENCING; GLIOBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; UPREGULATION; CELL SURVIVAL; DRUG EFFECTS; GENETICS; GLIOMA; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORTEZOMIB; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; GENE SILENCING; GLIOBLASTOMA; GLIOMA; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84927135293     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3875     Document Type: Article

References (43)

1. Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R and Amiot M: Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res 67:5418-5424, 2007.
2. Chen D, Frezza M, Schmitt S, Kanwar J and Dou QP: Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets 11:239-253, 2011.
3. Lesinski GB, Raig ET, Guenterberg K, Brown L, Go MR, Shah NN, Lewis A, Quimper M, Hade E, Young G, et al: IFN-alpha and bortezomib overcome Bcl-2 and Mcl-1 overexpression in melanoma cells by stimulating the extrinsic pathway of apoptosis. Cancer Res 68:8351-8360, 2008.
4. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R and Pazdur R: Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13:5291-5294, 2007.
5. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M and Dang CV: Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 58:4342-4348, 1998.
6. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, et al: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867-4874, 2006.
7. Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, et al: Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol 24:5025-5033, 2006.
8. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, Purner M, Lee SP, Wilson J, Morrison B, et al: Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 24:937-944, 2006.
9. Strauss SJ, Higginbottom K, Juliger S, Maharaj L, Allen P, Schenkein D, Lister TA and Joel SP: The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines. Cancer Res 67:2783-2790, 2007.
10. Fribley A and Wang CY: Proteasome inhibitor induces apoptosis through induction of endoplasmic reticulum stress. Cancer Biol Ther 5:745-748, 2006.
11. Lioni M, Noma K, Snyder A, Klein-Szanto A, Diehl JA, Rustgi AK, Herlyn M and Smalley KS: Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway. Cancer Ther 7:2866-2875, 2008.
12. Zhang L, Lopez H, George NM, Liu X, Pang X and Luo X: Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Cell Death Differ 18:864-873, 2011.
13. Kozopas KM, Yang T, Buchan HL, Zhou P and Craig RW: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci USA 90:3516-3520, 1993.
14. Zhang B, Gojo I and Fenton RG: Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99:1885-1893, 2002.
15. Eramo A, Ricci-Vitiani L, Zeuner A, Pallini R, Lotti F, Sette G, Pilozzi E, Larocca LM, Peschle C and De Maria R: Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 13:1238-1241, 2006.
16. Strik H, Deininger M, Streffer J, Grote E, Wickboldt J, Dichgans J, Weller M and Meyermann R: BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J Neurol Neurosurg Psychiatry 67:763-768, 1999.
17. Stegh AH, Kim H, Bachoo RM, Forloney KL, Zhang J, Schulze H, Park K, Hannon GJ, Yuan J, Louis DN, et al: Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma. Genes Dev 2:98-111, 2007.
18. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, et al: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22:2108-2121, 2004.
19. Frankel A, Man S, Elliott P, Adams J and Kerbel RS: Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 6:3719-3728, 2000.
20. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, Adams J, Elliott P and Van Waes C: Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7:1419-1428, 2001.
21. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J and McConkey DJ: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 1:1243-1253, 2002.
22. Kukreja A, Hutchinson A, Mazumder A, et al: Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications. Br J Haematol 136:106-110, 2007.
23. Adams J: The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4:349-360, 2004.
24. Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell 79:13-21, 1994.
25. Hochstrasser M: Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 7:215-223, 1995.
26. Ciechanover A: The ubiquitin-proteasome pathway: On protein death and cell life. EMBO J 17:7151-7160, 1998.
27. Peters JM, Cejka Z, Harris JR, Kleinschmidt JA and Baumeister W: Structural features of the 26 S proteasome complex. J Mol Biol 234:932-937, 1993.
28. Engel RH, Brown JA, Von Roenn JH, O'Regan RM, Bergan R, Badve S, Rademaker A and Gradishar WJ: A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 25:733-737, 2007.
29. Berenson JR, Ma HM and Vescio R: The role of nuclear factorkappaB in the biology and treatment of multiple myeloma. Semin Oncol 28:626-633, 2001.
30. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJ, et al: Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res 65:6282-6293, 2005.
31. Domina AM, Smith JH and Craig RW: Myeloid cell leukemia 1 is phosphorylated through two distinct pathways, one associated with extracellular signal-regulated kinase activation and the other with G2/M accumulation or protein phosphatase 1/2A inhibition. J Biol Chem 275:21688-21694, 2000.
32. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 9:1136-1144, 2003.
33. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S, Oyesanya RA, Dasgupta S, Dent P, Grant S, et al: Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 20:1397-1411, 2011.
34. Le Gouill S, Podar K, Harousseau JL and Anderson KC: Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 3:1259-1262, 2004.
35. Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R and Amiot M: Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x (L) is an essential survival protein of human myeloma cells. Blood 100:194-199, 2002.
36. Clohessy JG, Zhuang J, de Boer J, Gil-Gomez G and Brady HJ: Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J Biol Chem 281:5750-5759, 2006.
37. Craig RW: MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 16:444-454, 2002.
38. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM and Huang DC: Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19:1294-1305, 2005.
39. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM and Huang DC: Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 17:393-403, 2005.
40. Han J, Goldstein LA, Gastman BR and Rabinowich H: Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J Biol Chem 281:10153-10163, 2006.
41. Gomez-Bougie P, Bataille R and Amiot M: The imbalance between Bim and Mcl-1 expression controls the survival of human myeloma cells. Eur J Immunol 34:3156-3164, 2004.
42. Leu JI, Dumont P, Hafey M, Murphy ME and George DL: Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol 6:443-450, 2004.
43. Weng C, Li Y, Xu D, Shi Y and Tang H: Specific cleavage of Mcl-1 by caspase-3 in tumor necrosis factor-related apoptosisinducing ligand (TRAIL)-induced apoptosis in Jurkat leukemia T cells. J Biol Chem 280:10491-10500, 2005.